Acumen pharmaceuticals inc
ABOS 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
公司發布財報數據季度不足，尚無法提供評分
ABOS 近期報酬表現
2.01%
Acumen pharmaceuticals inc
0.29%
同產業平均
1.03%
S&P500
與 ABOS 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
PRTA | Prothena corporation plc | 3 分 | 2 分 | 3 分 | 3 分 | 1 分 | |
BIIB | Biogen inc | 5 分 | 3 分 | 4 分 | 3 分 | 1 分 | |
SXTP | 60 degrees pharmaceuticals inc | - | 1 分 | 2 分 | 1 分 | 1 分 | |
LVTX | Lava therapeutics nv | 2 分 | 3 分 | 4 分 | 1 分 | 1 分 | |
RCKT | Rocket pharmaceuticals inc | 2 分 | 3 分 | 2 分 | 2 分 | 1 分 |
- PRTA Prothena corporation plc價值 3 分趨勢 2 分波段 3 分籌碼 3 分股利 1 分查看更多
ABOS 公司資訊
Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a disease-modifying approach to target underlying cause of Alzheimer's disease (AD). The Company is focused on focused on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), in clinical development following Phase I results in early AD patients (patients with mild cognitive impairment or mild dementia due to Alzheimer's pathology). Sabirnetug is a recombinant humanized immunoglobulin gamma 2 (IgG2), monoclonal antibody (mAb) that selectively targets the anti-amyloid-beta oligomer (AbOs), has demonstrated functional and protective effects in in-vitro assays, and has demonstrated in-vivo safety and pharmacologic activity in multiple animal species including transgenic models for AD. The Company is developing sabirnetug for intravenous (IV), administration every four weeks for the treatment of early AD.